Please assess the completion status of the following clinical trial:

Trial Title: Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* B-CLL~* Age \>18~* ECOG performance status 0-2~* Previous Rituximab containing induction treatment of the CLL in 1st or 2nd line~* Patient must be in complete remission or partial remission after an induction treatment containing rituximab~* ANC (absolute neutrophil count) \> 1,0 x 10e9 /L~* Life expectancy \> 6 months~* Patient´s written informed consent~* Patient using a reliable means of contraception for the duration of the treatment including 2 months thereafter~Exclusion Criteria:~* Active uncontrolled bacterial, viral or fungal infection~* Significantly reduced organ functions and bone marrow dysfunction not due to CLL~* creatinine clearance of below 30mL/min~* Patients with a history of other malignancies within 2 years prior to study entry~* Patients with a history of severe cardiac disease~* Other known comorbidity with the potential to dominate survival~* Transformation to aggressive B-cell malignancy~* Hypersensitivity with anaphylactic reaction to humanized monoclonal antibodies or any of the applied drugs~* Medical condition requiring prolonged (\> 1 month) use of oral corticosteroids~* Pregnant or breast feeding women~* Any coexisting medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab (Type: EXPERIMENTAL): Treatment with Rituximab 375 mg/m² every 3 months for 24 months
- Observation (Type: NO_INTERVENTION): Observation for 24 months

Based on this trial design, predict the completion outcome and termination type (if applicable).